[3 min watch] Skin Cancer Update with Prof Giuseppe Argenziano [December 2019]

skin cancer update

In this month’s skin cancer update video, Professor Giuseppe Argenziano discusses the case of a flat facial lesion on a 60-year-old woman. Continue reading “[3 min watch] Skin Cancer Update with Prof Giuseppe Argenziano [December 2019]”

[7 min read] How much sun causes melanoma?

melanoma treatment

QIMR Berghofer researchers have shown that 22 different genes help to determine how much sun exposure a person needs to receive before developing melanoma. Continue reading “[7 min read] How much sun causes melanoma?”

[4 min read] Blocking key regulator could treat non-melanoma skin cancers

The outer layer of the skin completely replaces itself every two to four weeks, but when this process is blocked, cancer can grow. A new study from researchers at the University of Pennsylvania has now identified a key regulator of that block known as LSD1, as well as a way to genetically influence the skin to grow in a way that prevents this block from happening. Continue reading “[4 min read] Blocking key regulator could treat non-melanoma skin cancers”

[3 min watch] Skin Cancer Update with Prof Giuseppe Argenziano [November 2019]

skin cancer update

In this month’s skin cancer update video, Professor Giuseppe Argenziano discusses the option of removing the crust covering a lesion in-clinic rather than prescribing a topical treatment and asking the patient to come back. Continue reading “[3 min watch] Skin Cancer Update with Prof Giuseppe Argenziano [November 2019]”

[5 min read] Unique to Australia: Decline in melanoma mortality

Assessment of trends of melanoma incidence and mortality in Australia reveals a recent plateauing and reduction in melanoma age-standardised mortality1, which is unique to Australia (see figure 1). Continue reading “[5 min read] Unique to Australia: Decline in melanoma mortality”

[4 min read] Personalised nanovaccines for melanoma

A study has found that personalised nanovaccines are safe, well tolerated, and have an effect in melanoma.
Porous silicon and adenovirus-based bio-hybrid nanovaccines were developed in a study carried out at the University of Helsinki, providing new insights on the structure and efficacy of these systems as therapeutic cancer nanovaccines.
Immunotherapy is revolutionising cancer treatment, achieving durable and long-term responses in patients. However, due to immunotherapeutic resistance, only some patients experience a positive outcome. Combinations of immunotherapeutics can overcome the drug resistance, so the administration of a cancer vaccine or an oncolytic virus followed by immune antibodies is under investigation.
Nevertheless, there is an unmet need for powerful, safe vaccines. Nanoparticles, in particular porous silicon nanoparticles, present ideal characteristics to formulate nanovaccines, as a result of their size-specific targeting to the lymphoid organs, to their intrinsic adjuvant effect, and to the possibility to simultaneously load adjuvants and antigens.
M.Sc. Pharma Flavia Fontana describes in her doctoral thesis the development of nanovaccines from the materials to the pre-clinical proof of concept trials.
Fontana developed a bio-hybrid multistage nanovaccine formulation and evaluated its anti-cancer efficacy in murine tumour models. Fontana’s study shows that the treatment could stimulate the immune system of the mice and control melanoma tumours alone or when combined with antibodies, which are the present standard treatment. Fontana proposed bio-hybrid cell membrane technology as an innovative antigenic source.
The personalised nanovaccines described in Fontana’s thesis are safe and well tolerated. The core particle will be the same for all patients, while the cell membrane wrapping will change for each patient because it will derive from parts of their tumour biopsy.
The future developments of the nanovaccines will take them closer to the clinics by evaluating the feasibility of the approach with real patient tumours.

Interested in skin cancer medicine?

The HealthCert Professional Diploma programs offer foundation to advanced training in skin cancer medicine, skin cancer surgery or dermoscopy and provide an essential step towards subspecialisation. All programs are university quality-assured, CPD-accredited and count towards multiple Master degree pathways and clinical attachment programs in Australia and overseas. The programs are delivered online and/or face-to-face across most major cities of Australia.

Courses in Skin Cancer Medicine:
Melbourne | Gold Coast | Brisbane | Sydney | Online

Courses in Skin Cancer Surgery:
Melbourne | Gold Coast | Brisbane | Sydney

Online courses in Dermoscopy:
Trimester 1: Jan | Trimester 2: May | Trimester 3: Sep


Read more recent research.

Source: Fontana F., 2019. Biohybrid Cloaked Nanovaccines for Immunotherapy. Dissertationes Scholae Doctoralis Ad Sanitatem Investigandam Universitatis Helsinkiensis, 47/2019, pp.78. ISBN 987-951-51-5286-2 (Paperback), ISBN 978-951-51-5287-9 (PDF, http://ethesis.helsinki.fi), ISSN 2342-316

[5 min read] How gene variations affect melanoma risk

melanoma risk

Australian scientists have identified a way to help primary care physicians determine a patient’s risk of developing melanoma.

A team at The University of Queensland Diamantina Institute uncovered the specific gene variations affecting the number and types of moles that appear on the body, and their role in causing skin cancer. Continue reading “[5 min read] How gene variations affect melanoma risk”

[7 min read] 45 new genetic causes of non-melanoma skin cancer identified

genetic causes

An Australian study has discovered 45 new genetic variants that put people at higher risk of developing basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) – the most common form of skin cancers. Continue reading “[7 min read] 45 new genetic causes of non-melanoma skin cancer identified”

[4 min watch] Skin Cancer Update with Prof Giuseppe Argenziano [October 2019]

skin cancer update

In this month’s skin cancer update video, Professor Giuseppe Argenziano discusses differential diagnoses for lesions on the scalp, especially in elderly people. Continue reading “[4 min watch] Skin Cancer Update with Prof Giuseppe Argenziano [October 2019]”

[4 min read] How to biopsy pigmented skin lesions

pigmented skin lesion

A recent article published in Australian Doctor warned against shave biopsies for pigmented skin lesions suspicious for melanoma. Below, Professor David Wilkinson offers guidance for the best-practice approach to biopsying these lesions in general practice. Continue reading “[4 min read] How to biopsy pigmented skin lesions”